Novartis AG ADR (NVS)vsStevanato Group SpA (STVN)
NVS
Novartis AG ADR
$160.50
-0.19%
HEALTHCARE · Cap: $302.86B
STVN
Stevanato Group SpA
$15.53
-1.71%
HEALTHCARE · Cap: $3.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4496% more annual revenue ($57.36B vs $1.25B). NVS leads profitability with a 17.5% profit margin vs 11.3%. STVN appears more attractively valued with a PEG of 1.70. STVN earns a higher WallStSmart Score of 59/100 (C).
NVS
Hold48
out of 100
Grade: D+
STVN
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.6%
Fair Value
$95.76
Current Price
$160.50
$64.74 premium
Margin of Safety
+67.9%
Fair Value
$48.58
Current Price
$15.53
$33.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : STVN
The primary concerns for STVN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
STVN carries more volatility with a beta of 0.80 — expect wider price swings.
STVN is growing revenue faster at 7.6% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
STVN scores higher overall (59/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?